Severity
Moderate
FDA Drug recall · Reported January 9, 2019
Lack of sterility assurance.
Hiers Enterprises, LLC dba Northwest Compounding Pharmacy recalled Testosteron Cypionate liquid 200mg/ml, RX, glass vial - a moderate-severity action.
Testosteron Cypionate liquid 200mg/ml, RX, glass vial was recalled by Hiers Enterprises, LLC dba Northwest Compounding Pharmacy in January 9, 2019. Reason: Lack of sterility assurance.. Check the official notice for the remedy. Verify recall #D-0401-2019 with the FDA Drug before acting.
The recall
Hiers Enterprises, LLC dba Northwest Compounding Pharmacy issued this moderate-severity FDA Drug recall-Lack of sterility assurance..
Sourced from official FDA Drug enforcement records. Verify recall #D-0401-2019 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.
This FDA Drug action (record #D-0401-2019) was formally reported on January 9, 2019, with the manufacturer initiating the action on January 2, 2019. It is classified under Moderate severity (Class II), with a current status of Terminated. Hiers Enterprises, LLC dba Northwest Compounding Pharmacy is listed as the recalling firm, operating out of Roseburg, OR. Federal records list the affected scope as 200 ml.
The documented reason for this recall is: Lack of sterility assurance. Distribution data in the federal record shows the product reached: Product was distributed exclusively in the state of Oregon to 3 Medical facilities, 1 Physician's office and 80 consumers/patients. These are compounded products - labels vary for each compound - specific to each pat…. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.
Within the same product category the archive holds 6 closely related recalls, 5 from FDA Drug - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.
Where this recall sits in its category - 14,287 drugs & medications recalls on record
Of 101,704 recalls in the database, 24,878 are high severity, 72,426 moderate, and 4,400 low. This recall is classified moderate severity.
Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.
Severity
Moderate
Affected scope
200 ml
Related Recalls
6
5 from same agency
Testosteron Cypionate liquid 200mg/ml, RX, glass vial
Lack of sterility assurance.
| Attribute | Value |
|---|---|
| Agency | U.S. Food and Drug Administration |
| Severity class | Moderate (Class II) |
| Status | Terminated |
| Recall number | D-0401-2019 |
| Date reported | January 9, 2019 |
| Date initiated | January 2, 2019 |
| Recalling firm | Hiers Enterprises, LLC dba Northwest Compounding Pharmacy |
| Firm location | Roseburg, OR |
| Affected scope | 200 ml |
| Distribution | Product was distributed exclusively in the state of Oregon to 3 Medical facilities, 1 Physician's office and 80 consumers/patients. These are compounded products - labels vary for each compound - specific to each patient. Firm did not … |
Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.
What to do with this recall
Match your product against the recall record, then act on the agency remedy.
This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.
Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.
AbbVie Inc. · 2026-06-03
Llorens Pharmaceuticals International Division, Inc. · 2026-05-27
Safecor Health, LLC · 2026-05-27
IntegraDose Compounding Services LLC · 2026-05-27
Lupin Pharmaceuticals Inc. · 2026-05-27
Compare this recall with PRED MILD, prednisolone acetate ophthalmic suspension, USP,… →
Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Drug, reported January 9, 2019. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of July 2026.